Literature DB >> 22177578

How might HPV testing be integrated into cervical screening?

Hormuzd A Katki1, Nicolas Wentzensen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22177578      PMCID： PMC3253934          DOI： 10.1016/S1470-2045(11)70334-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  10 in total

Review 1.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

2.  Benefits and risks of HPV testing in cervical cancer screening.

Authors:  Philip E Castle; Hormuzd A Katki
Journal:  Lancet Oncol       Date:  2010-01-18       Impact factor: 41.316

3.  Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

Authors:  Hormuzd A Katki; Walter K Kinney; Barbara Fetterman; Thomas Lorey; Nancy E Poitras; Li Cheung; Franklin Demuth; Mark Schiffman; Sholom Wacholder; Philip E Castle
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

4.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.

Authors:  Susanne K Kjær; Kirsten Frederiksen; Christian Munk; Thomas Iftner
Journal:  J Natl Cancer Inst       Date:  2010-09-14       Impact factor: 13.506

5.  Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.

Authors:  Dorien C Rijkaart; Johannes Berkhof; Lawrence Rozendaal; Folkert J van Kemenade; Nicole W J Bulkmans; Daniëlle A M Heideman; Gemma G Kenter; Jack Cuzick; Peter J F Snijders; Chris J L M Meijer
Journal:  Lancet Oncol       Date:  2011-12-14       Impact factor: 41.316

6.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.

Authors:  Guglielmo Ronco; Paolo Giorgi-Rossi; Francesca Carozzi; Massimo Confortini; Paolo Dalla Palma; Annarosa Del Mistro; Bruno Ghiringhello; Salvatore Girlando; Anna Gillio-Tos; Laura De Marco; Carlo Naldoni; Paola Pierotti; Raffaella Rizzolo; Patrizia Schincaglia; Manuel Zorzi; Marco Zappa; Nereo Segnan; Jack Cuzick
Journal:  Lancet Oncol       Date:  2010-01-18       Impact factor: 41.316

7.  Risk estimation for the next generation of prevention programmes for cervical cancer.

Authors:  Hormuzd A Katki; Sholom Wacholder; Diane Solomon; Philip E Castle; Mark Schiffman
Journal:  Lancet Oncol       Date:  2009-09-18       Impact factor: 41.316

8.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

Authors:  Marie-Hélène Mayrand; Eliane Duarte-Franco; Isabel Rodrigues; Stephen D Walter; James Hanley; Alex Ferenczy; Sam Ratnam; François Coutlée; Eduardo L Franco
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

9.  HPV screening for cervical cancer in rural India.

Authors:  Rengaswamy Sankaranarayanan; Bhagwan M Nene; Surendra S Shastri; Kasturi Jayant; Richard Muwonge; Atul M Budukh; Sanjay Hingmire; Sylla G Malvi; Ranjit Thorat; Ashok Kothari; Roshan Chinoy; Rohini Kelkar; Shubhada Kane; Sangeetha Desai; Vijay R Keskar; Raghevendra Rajeshwarkar; Nandkumar Panse; Ketayun A Dinshaw
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245

10.  Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.

Authors:  Joakim Dillner; Matejka Rebolj; Philippe Birembaut; Karl-Ulrich Petry; Anne Szarewski; Christian Munk; Silvia de Sanjose; Pontus Naucler; Belen Lloveras; Susanne Kjaer; Jack Cuzick; Marjolein van Ballegooijen; Christine Clavel; Thomas Iftner
Journal:  BMJ       Date:  2008-10-13
  10 in total
  4 in total

1.  Cervical cancer trends in the United States: a 35-year population-based analysis.

Authors:  Olusola Adegoke; Shalini Kulasingam; Beth Virnig
Journal:  J Womens Health (Larchmt)       Date:  2012-07-20       Impact factor: 2.681

2.  Long-term costs of introducing HPV-DNA post-treatment surveillance to national cervical cancer screening in Ireland.

Authors:  Maria Agapova; Andrea Duignan; Alan Smith; Ciaran O'Neill; Anirban Basu
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-09-17       Impact factor: 2.217

3.  Physical labeling of papillomavirus-infected, immortal, and cancerous cervical epithelial cells reveal surface changes at immortal stage.

Authors:  K Swaminathan Iyer; R M Gaikwad; C D Woodworth; D O Volkov; Igor Sokolov
Journal:  Cell Biochem Biophys       Date:  2012-06       Impact factor: 2.194

4.  Ultrabright fluorescent mesoporous silica nanoparticles for prescreening of cervical cancer.

Authors:  Shajesh Palantavida; Nataliia V Guz; C D Woodworth; I Sokolov
Journal:  Nanomedicine       Date:  2013-05-09       Impact factor: 5.307
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.